Abstract:Abstract Objective Evaluation of the efficacy of adeno‐associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap (AAV2‐VEGF‐Trap) alone or combination with paclitaxel in a mouse model of triple‐negative breast cancer (TNBC) using diffusion‐weighted magnetic resonance imaging (DW‐MRI) and in vivo fluorescence imaging. Materials and Methods Xenografted TNBC tumors were established by subcutaneous injection of MDA‐MB‐231 cells into nude mice. Tumors were treated with AAV2‐VEGF‐Trap, paclitaxel, AAV2‐VEGF‐Trap combined with paclitaxel and control. A 7.0‐Tesla magnetic resonance (MR) was used to obtain the apparent diffusion coefficient (ADC) values and ΔADC values. In vivo fluorescence imaging coupled with the optical imaging probe AngioSense680 EX was acquired to obtain average luminous intensity values. Immunohistochemical staining of tumor Ki‐67 and vascular endothelial cell marker antigen (CD31) were used to evaluate the effects on tumor proliferation and angiogenesis. Results The combination of AAV2‐VEGF‐Trap with paclitaxel exhibited greater tumor growth inhibition compared with the other groups. The ADC values in the paclitaxel group and the AAV2‐VEGF‐Trap in combination with paclitaxel group were significant greater compared with the control group, and the ΔADC values of all treatment groups were significantly increased compared with the control group on the 14th day after administration. Decreased microvessel density and luminous intensity in the treatment groups that contain AAV2‐VEGF‐Trap were observed. Reduced proliferation activity was noted in groups that contained paclitaxel. Conclusion AAV2‐VEGF‐Trap inhibits TNBC growth though inhibiting tumor neovascularization with a single intravenous injection, and AAV2‐VEGF‐Trap exhibits a synergistic effect when used in combination with paclitaxel for TNBC neoadjuvant therapy. In vivo fluorescence imaging can detect the anti‐angiogenesis effect of AAV2‐VEGF‐Trap early and noninvasively. DW‐MRI can longitudinally monitor the neoadjuvant efficacy of TNBC.

Adeno-associated Virus 2 Mediated Gene Transfer of Vascular Endothelial Growth Factor Trap: a New Treatment Option for Glioma.

AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression.

Combination Therapy Of Vegf-Trap And Gemcitabine Results In Improved Anti-Tumor Efficacy In A Mouse Lung Cancer Model

Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model

Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

Adeno‐associated virus (AAV)-based gene therapy for glioblastoma

Clinical applications of VEGF-trap (aflibercept) in cancer treatment.

Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin.

Study of Diffusion‐weighted Magnetic Resonance Imaging in the Evaluation of the Response to AAV2‐VEGF‐Trap Neoadjuvant Treatment in a Triple‐negative Breast Cancer Animal Model

Exth-04. Combination Of Bevacizumab Enhances The Anti-Tumor Efficacy Of Ad-Sge-Reic For Glioma

Efficacy and Safety of Bevacizumab Combined with Temozolomide in the Treatment of Glioma: A Systematic Review and Meta-Analysis of Clinical Trials

Investigation of a Plasmid Containing a Novel Immunotoxin VEGF165‐PE38 Gene for Antiangiogenic Therapy in a Malignant Glioma Model

Efficacy of Antiangiogenic Targeted Immunotoxin DTAT and DTATEGF Against Glioblastoma Multiforme.

Anti-VEGFR2 Monoclonal Antibody(msb0254) Inhibits Angiogenesis and Tumor Growth by Blocking the Signaling Pathway Mediated by VEGFR2 in Glioblastoma.

Efficacy and Safety of Bevacizumab for the Treatment of Glioblastoma.

Single Administration of AAV Vector in Muscle Resulted in a High-Level and Prolonged Secretion of Angiostatin into Blood

Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth

Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.

[Anti-Glioma Effect of Combination of Bfgf-Sirna and Vpr in Nude Mice].

Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms

Effect of AAV-AS and cytoxan on subcutaneous glioma in rats